
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsAcumen Reports Sabirnetug Failure Despite Amyloid ReductionAcumen Pharmaceuticals reported that sabirnetug (ACU193) failed to demonstrate clinical benefit in the Phase 2 ALTITUDE-AD trial at either dose, despite significant amyloid plaque reduction.Fact-Checked
Clinical TrialsAlnylam’s Brezosiran Lowers Mutant Huntingtin by Up to 64%Alnylam’s investigational RNAi therapeutic brezosiran demonstrated dose-dependent mutant huntingtin reduction in its Phase 1b Huntington’s disease study, with mean reductions of 60–64% in the highest dose group at…Fact-Checked
New Drug ApprovalSun’s ILUMYA Gains New FDA Indication Following INSPIRE TrialsSun Pharma’s ILUMYA (tildrakizumab) has received FDA approval for adults with active psoriatic arthritis, expanding its use beyond plaque psoriasis.Fact-Checked
Clinical TrialsGeron Discontinues IMpactMF Trial After DMC Flags OS Endpoint RiskGeron has discontinued its Phase 3 IMpactMF trial evaluating imetelstat in relapsed or refractory myelofibrosis after an independent Data Monitoring Committee concluded that the study was unlikely to…Fact-Checked
Clinical TrialsOSE’s Tedopi Shows Encouraging Survival Results in NSCLC TrialOSE Immunotherapeutics reported one-year overall survival rates of 47% and 46% with Tedopi plus docetaxel and Tedopi plus nivolumab, respectively, in the Combi-TED Phase 2 trial.Fact-Checked
Clinical TrialsaTyr’s Efzofitimod Shows Mixed Results in SarcoidosisaTyr Pharma’s Phase 3 EFZO-FIT trial failed to demonstrate a significant steroid-sparing benefit for efzofitimod in pulmonary sarcoidosis.Fact-Checked
Clinical TrialsCervoMed Reports Mixed Findings for Neflamapimod in DLBCervoMed’s Phase 2b RewinD-LB trial failed to confirm neflamapimod’s primary CDR-SB endpoint in dementia with Lewy bodies.Fact-Checked
Clinical TrialsAscletis’ Oral ASC30 Delivers Up to 1.7% HbA1c ReductionAscletis Pharma reported placebo-adjusted HbA1c reductions of 1.6% to 1.7% with oral GLP-1 receptor agonist ASC30 in a 13-week Phase II type 2 diabetes study.Fact-Checked
Clinical TrialsOno Advances ONO-1110 Despite Failed Pain Trial EndpointsOno Pharmaceutical plans further clinical studies of ONO-1110 in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis after exploratory pain-score signals emerged in Phase 2 analyses.Fact-Checked
Clinical TrialsHUTCHMED’s SAFFRON Shows Benefit from Adding Savolitinib After Osimertinib FailureHUTCHMED’s global Phase III SAFFRON trial demonstrated significant improvements in progression-free and overall survival with savolitinib plus osimertinib versus platinum-based chemotherapy in patients with EGFR-mutated NSCLC and high…Fact-Checked
Clinical TrialsHUTCHMED Reports 24.9-Month PFS With First-Line Savolitinib CombinationHUTCHMED’s Phase III SANOVO trial found that savolitinib plus osimertinib extended median progression-free survival by 11.1 months versus osimertinib alone in previously untreated EGFR-mutated, MET-overexpressing advanced NSCLC.Fact-Checked
Clinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Cancer TrialBioNTech and DualityBio’s phase 3 DYNASTY-Breast02 trial met its primary PFS endpoint for trastuzumab pamirtecan in HR-positive/HER2-low metastatic breast cancer.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.